the association between Ki67 and clinical features in patients with advanced EGFR-positive lung adenocarcinoma

the association between Ki67 and clinical features in patients with advanced EGFR-positive lung adenocarcinoma - EGFR-Ki67 study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042886

Enrollment

Registered

2021-01-02

Start date

2021-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

40 cases diagnosed advanced lung adenocarcinoma. The 20 cases were EGFR mutation positive and treated with EGFR inhibitors, and the other 20 cases are EGFR mutation negative and treated with chemotherapy and/or immunotherapy.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with advanced non-small-cell lung cancer. Written informed consent is obtained from all the patients.

Exclusion criteria

Exclusion criteria: Patients having an overlap cancer with activity Patients that an doctor judged to be inappropriate.

Design outcomes

Primary

Measure	Time frame
We measure the staining intensity of Ki67 in EGFR-positive and EGFR-negative cases, and examine the effect with EFGR inhibitors and prognosis of according to the intensity of Ki67 in EGFR-positive cases.	—

Countries

Japan

Contacts

Public ContactNaruo Yoshimura

Tohoku Medical and Pharmaceutical University Division of Respiratory Medicine

y-naruo@sc4.so-net.ne.jp0222908850

Outcome results